The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting

被引:91
|
作者
Ciechanover, A [1 ]
机构
[1] Technion Israel Inst Technol, Dept Biochem, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
关键词
cancer; neurodegeneration; protein degradation; proteasome; ubiquitin;
D O I
10.1042/BST0310474
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Until the early 1980s, protein degradation was a neglected research area, and scientists were mostly busy deciphering the genetic code and its translation to the proteome. Destruction of cellular proteins was thought to be a scavenger, non-specific and dead-end process. Although it was known that proteins do turn over, the large extent and high specificity of the process, whereby distinct proteins have half-lives that range from a few minutes to several days, was not appreciated. The discovery of the lysosome by Christian de Duve did not change this view significantly, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. it is clear now that degradation of cellular proteins via the ubiquitin system is a highly complex, temporally controlled and tightly regulated process that plays major roles in a variety of basic pathways and processes during cell life and death, and in health and disease. The system is involved in targeting many cellular proteins, among them cell cycle regulators, growth- and differentiation-controlling factors, transcriptional activators, cell-surface receptors and ion channels, endoplasmic reticulum proteins, antigenic proteins destined for presentation on class I MHC molecules, and abnormal/misfolded proteins. Consequently, it is involved in regulating many basic cellular processes, such as cell cycle and division, growth and differentiation, signal transduction and transcription, modulation of the secretory and endocytic pathways, the immune and inflammatory responses, and quality control. With the multitude of substrates targeted and the numerous processes involved, it is not surprising that aberrations in the pathway have been implicated in the pathogenesis of many diseases, with certain malignancies and neurodegenerative disorders being ranked among them.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [21] Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting
    Ciechanover, Aaron
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (04) : 341 - 355
  • [22] Intracellular protein degradation: From a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting
    Ciechanover, Aaron
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (12) : 3400 - 3410
  • [23] Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting
    Ciechanover, Aaron
    [J]. RAMBAM MAIMONIDES MEDICAL JOURNAL, 2012, 3 (01):
  • [24] Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting
    Ciechanover, Aaron
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2006, 231 (07) : 1197 - 1211
  • [25] DEVELOPMENT OF A MECHANISM-BASED DRUG-DISEASE MODELING PLATFORM FOR TYPE 2 DIABETES MELLITUS.
    Hurtado, F. K.
    Gaitonde, P.
    Garhyan, P.
    Chien, J. Y.
    Schmidt, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S37 - S37
  • [26] Port delivery system: a novel drug delivery platform to treat retinal diseases
    Khanani, Arshad M.
    Aziz, Aamir A.
    Weng, Christina Y.
    Lin, Weijie Violet
    Vannavong, Jordyn
    Chhablani, Jay
    Danzig, Carl J.
    Kaiser, Peter K.
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (11) : 1571 - 1576
  • [27] Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3
    Sahu, A
    Pangburn, MK
    [J]. BIOCHEMICAL PHARMACOLOGY, 1996, 51 (06) : 797 - 804
  • [28] DRUG EFFECTS ON THE CARDIOVASCULAR SYSTEM - DEVELOPMENT OF A MECHANISM-BASED PHARMACODYNAMIC MODEL TO IMPROVE TRANSLATION DRUG RESEARCH
    Snelder, N.
    Ploeger, B.
    Danhof, M.
    Stanski, D.
    Rigel, D.
    Webb, R.
    Feldman, D.
    Luttringer, O.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S24 - S24
  • [29] Using Human iPSCs for Psychiatric Disorder Disease Modeling and Mechanism-Based Drug Discovery
    Wen, Zhexing
    Guo, Ziyuan
    Wang, Xinyuan
    Kim, Namshik
    Ross, Christopher
    Margolis, Russell
    Christian, Kimberly
    Chen, Gong
    Zheng, Wei
    Xia, Menghang
    Song, Hongjun
    Ming, Guo-li
    [J]. BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S290 - S291
  • [30] MECHANISM-BASED ENZYME INACTIVATORS IN RATIONAL DRUG DISCOVERY - CURING DISEASES WITH BIOCHEMICAL TROJAN HORSE REAGENTS
    NANGIA, A
    CHANDRAKALA, PS
    [J]. CURRENT SCIENCE, 1995, 68 (07): : 699 - 714